Table 1 The effects of lapatinib on the variables of the echocardiogram and left ventricular pressure.

From: Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

 

Cardiac cycle

Variables

Control

0.3 mg/kg

3 mg/kg

P value

30 min

30 min

60 min

Dimensions

End-diastole

LVDd

(mm)

25 ± 1

24 ± 1

23 ± 1

24 ± 1

0.54

LVEDV

(mL)

22 ± 3

21 ± 2

19 ± 2

20 ± 2

0.52

End-systole

LVDs

(mm)

17 ± 1

16 ± 1

16 ± 1

16 ± 1

0.39

LVESV

(mL)

9 ± 1

8 ± 1

7 ± 1

9 ± 2

0.24

Systolic function

Ejection

period

EF (Teich)

(%)

62 ± 2

61 ± 2

63 ± 3

62 ± 2

0.18

%FS

(%)

31 ± 2

31 ± 1

33 ± 3

32 ± 2

0.27

Diastolic function

Passive

filling

E/A

 

1.27 ± 0.22

1.28 ± 0.25

1.29 ± 0.27

1.10 ± 0.19

0.52

E′

(m/s)

0.064 ± 0.011

0.064 ± 0.013

0.060 ± 0.013

0.064 ± 0.012

0.87

E/E′

 

7.77 ± 0.80

7.70 ± 0.79

8.45 ± 0.96

7.25 ± 0.50

0.42

EDPVR

(mmHg/mL)

0.46 ± 0.07

0.59 ± 0.08

0.68 ± 0.19

0.72 ± 0.17

0.14

Active relaxation

IRT

(ms)

89.9 ± 6.6

93.0 ± 8.6

99.7 ± 9.7

114.5 ± 6.8

0.17

  1. Data are presented as mean ± SEM (n = 5). P values represent the statistical significances within a parameter evaluated with one-way repeated-measures analysis of variance. LVDd: Left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVDs: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; EF (Teich): ejection fraction assessed by Teichholz method; %FS: % fractional shortening; E/A: the peak velocities of E-wave/A-wave; E′: the peak velocity of E′-wave; E/E′: the peak velocities of E-wave/E′-wave; EDPVR: end-diastolic pressure-volume relationship = left ventricular end-diastolic pressure/LVEDV; and IRT: isovolumic relaxation time.